Biotie Therapies Corp. Stock Exchange Release 4 February 2013 at 11:30 a.m.
Change in the number of votes relating to Biotie Therapies Corp.`s shares
The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"), Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie Therapies Holding AG) has conveyed Biotie shares against consideration pursuant to the option programs as follows:
|January 2013|| Total (5/2011-|
| % of the total|
The conveyance of Biotie shares relates to the option plan of Synosia Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia") acquired by Biotie in February 2011. According to such Synosia share option plan, options have been granted to employees, former directors and consultants. In connection with the completion of the acquisition of Synosia, the option plan was amended so that instead of shares in Synosia an aggregate maximum of 14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued these 14,912,155 shares to its current subsidiary Synosia in connection with the acquisition to be further conveyed to the option holders when they potentially exercise their option rights in accordance with the terms and conditions of the option program.
The conveyed shares previously held by the Company`s subsidiary have not carried any voting rights. The parent company Biotie does not own any treasury shares. The conveyance does not affect the number of registered shares.
After the conveyances the changes are as follows:
| The increase of vote of the Company |
| A total amount of |
| The number of the|
Company`s share held
by the Group
| The total number |
Turku, 4 February 2013
Biotie Therapies Corp.
President and CEO
For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
NASDAQ OMX Helsinki Ltd
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Biotie Therapies Oyj via Thomson Reuters ONE